CV Therapeutics, Quintiles sales and marketing update

QTRN's Innovex Inc. subsidiary (Parsippany, N.J.) will exclusively market in the U.S. CVTX's ranolazine, which is in Phase III trials to treat chronic unstable angina. Innovex will provide a sales for...